Valatan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valatan

Understanding Valatan

Valatan is a pharmaceutical medication primarily utilized in the field of ophthalmology. It belongs to a class of drugs known as prostaglandin analogues. These compounds are synthetic versions of naturally occurring substances in the body that help regulate the flow of fluid within the eye.

Mechanism of Action

The eye continuously produces a clear fluid called aqueous humor, which provides nutrients and maintains the shape of the globe. In a healthy eye, the amount of fluid produced is balanced by the amount that drains out.

Valatan works by enhancing the body's natural drainage pathways. Specifically, it increases the outflow of aqueous humor through the uveoscleral route. By facilitating this drainage, the medication helps to manage the internal pressure of the eye, which is a critical factor in maintaining long-term ocular health.

Primary Uses

This medication is typically prescribed for individuals who require management of elevated intraocular pressure. This condition often occurs when the drainage system of the eye is not functioning efficiently, or when there is an overproduction of fluid.

High internal eye pressure is a primary characteristic of certain chronic ocular conditions, such as open-angle glaucoma and ocular hypertension. While these conditions may not always present immediate symptoms, maintaining pressure within a specific range is essential for protecting the optic nerve and preserving visual function.

Characteristics of Treatment

Valatan is formulated as an ophthalmic solution. Because it targets the internal mechanisms of the eye, it is applied topically. It is designed to provide a sustained effect on fluid drainage, typically requiring consistent application to remain effective. Unlike some other types of eye medications, prostaglandin analogues like Valatan are often noted for their ability to maintain stable pressure levels throughout the day and night.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Valatan?

Valatan: Possible Side Effects and Safety Information

The official safety documentation for Valsartan establishes a defined risk profile by classifying expected adverse reactions according to their frequency and affected body system. Adverse events are officially grouped into System-Organ Classes (SOC) by regulatory agencies.


Frequency-Classified Adverse Reactions

The frequency of reported adverse effects is determined by clinical trial data and regulatory review. Dizziness and headache are frequently reported, typically classified as Common. Hypotension (low blood pressure) is often classified as Common or Very Common, particularly in patients treated for heart failure. Effects classified as Uncommon may include vertigo, non-productive cough, and abdominal pain.


Serious Adverse Reactions and Restrictions

Official labeling highlights several serious safety considerations. The U.S. regulatory documents include a Boxed Warning regarding the risk of fetal toxicity, which can cause injury and death when the medicine is used during the second and third trimesters of pregnancy. Consequently, use during this period is contraindicated. Other serious documented reactions include angioedema (rapid swelling, potentially of the airway) and the risk of acute renal failure, particularly in susceptible individuals.

Specific constraints on use include the contraindication in patients with severe hepatic impairment, biliary cirrhosis, or cholestasis. The regulatory profile also notes that symptomatic hypotension is more likely to occur at treatment initiation or during dose titration, especially in volume-depleted patients. The drug is also contraindicated for concurrent use with Aliskiren in patients with diabetes.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Valatan (Valsartan) is primarily expected to cause an exaggeration of the medicine's core pharmacological effects. Regulatory documentation states that the most likely clinical manifestation of overdosage is profound hypotension (severely low blood pressure), which may be accompanied by a dangerously accelerated heart rate (tachycardia) or, less commonly, a slowed heart rate (bradycardia).


Documented Severe Outcomes

The official prescribing information warns that an overdose may lead to life-threatening clinical outcomes. These severe consequences explicitly documented include circulatory collapse, a state of shock resulting from inadequate tissue perfusion, and a depressed level of consciousness.


Emergency Actions

In the event of any suspected overdosage or the manifestation of severe symptoms such as collapse or shock, immediate medical attention must be sought. Official guidance mandates contacting a regional poison control centre for specific management advice. As there is no specific antidote known for Valsartan, and the drug is not removed from the plasma by dialysis due to its high protein binding, treatment required is strictly symptomatic and supportive until the patient is clinically stable. This supportive care is crucial for managing the severe hypotensive effects.

Therapeutic Uses of Valatan

What Valatan Treats: Main Uses and Benefits

Valatan is used for managing conditions characterized by increased physiological stress. This medication is commonly used to help manage chronic hypertension, symptomatic heart failure, and to support recovery after a heart attack. In specialized care contexts, it is considered relevant for addressing associated diabetic kidney disease in patients with high blood pressure.

The primary therapeutic purpose is to contribute to a reduction of systemic pressure, which may assist with easing the overall symptom load by targeting the underlying pressure that creates noticeable physiological strain on the cardiovascular system. This provides supportive relief when symptoms interfere with routine activities. The supportive role is relevant for managing the physiological strain on the heart and blood vessels during periods of heightened systemic burden.


Quick Fact: Relief for Chronic Pressure Burden

Valatan may assist with providing supportive relief during periods of chronic high blood pressure and helps manage the physiological strain on the heart muscle following acute cardiovascular events.

Regulatory References

  1. NIH MedlinePlus overview of Valsartan

Eligibility and Restrictions for Use

This section explains the official eligibility and non-eligibility rules for Valatan (valsartan) as documented in authoritative regulatory sources.

Populations for Whom Use is Prohibited or Restricted

Contraindicated (Must Not Use)

  • Pregnancy Status: Use is strictly prohibited during the second and third trimesters of pregnancy due to the documented risk of severe fetal injury and death. If pregnancy is detected, Valatan should be discontinued immediately.
  • Hypersensitivity: Patients with a known allergy or hypersensitivity to valsartan or any component of the formulation are officially excluded from use.
  • Severe Hepatic Impairment: Use is contraindicated in patients with severe hepatic impairment, biliary cirrhosis, or cholestasis.
  • Concomitant Medication: The drug is contraindicated in patients with diabetes mellitus who are concurrently receiving products containing aliskiren.

Restricted or Not Recommended

  • Pediatric Age: Use is not recommended in children younger than one year of age. Efficacy and safety data are limited or unestablished for children under six years of age. Use in children is generally established for hypertension only, in patients six years of age and older.
  • Lactation: Breastfeeding is not recommended during treatment.
  • Renal Impairment: The combination of valsartan and aliskiren is also contraindicated in patients with renal impairment (Glomerular Filtration Rate <60 mL/min/1.73 m^2).

Official Eligibility Summary

Official regulatory documents primarily define eligibility by establishing clear populations for whom use is prohibited (contraindicated). These prohibitions are centered on fetal safety during the latter stages of pregnancy, specific severe liver conditions, and a mandatory exclusion when combined with aliskiren in patients with diabetes or certain degrees of kidney impairment. Use in the pediatric population is limited by age, typically being restricted to children six years and older for the treatment of high blood pressure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

The co-administration of Valatan with Aliskiren is contraindicated (must not be taken together) in patients with Diabetes Mellitus or in those with moderate-to-severe renal impairment (defined as Glomerular Filtration Rate (GFR) < 60 mL/min/1.73 m^2). This restriction prevents the risk of severe hypotension, hyperkalemia, and worsening renal function.

Clinically Significant Interactions

Potassium-Elevating Agents

Co-administration with potassium-sparing diuretics (e.g., Spironolactone, Triamterene), potassium supplements, or salt substitutes containing potassium requires caution due to an increased risk of hyperkalemia (high serum potassium levels).

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Combining Valatan with NSAIDs, including selective COX-2 inhibitors, may lead to a greater risk of impaired kidney function, including acute renal failure, and can reduce the blood pressure-lowering effect of Valatan.

Transporter-Mediated Interactions

Valatan is a substrate for the hepatic uptake transporters OATP1B1 and OATP1B3. Medications that inhibit these transporters, such as Rifampicin, can significantly increase the plasma exposure (AUC and Cmax) of Valatan.

Food Interaction

Taking Valatan with food decreases the amount of drug absorbed into the body; however, the medicine may be taken without regard to meals.

Mechanism of Action

Valatan: Selective Inhibition of the OCAR Receptor

Valatan acts as an inhibitor of the Osteoclast-Activating Receptor (OCAR), a key regulatory protein in bone resorption. Binding to OCAR decreases the differentiation and function of osteoclasts, the multinucleated cells responsible for bone tissue breakdown. The downstream signaling cascade includes the modulation of key proteolytic enzymes, such as Cathepsin K and TRAP (Tartrate-Resistant Acid Phosphatase), thereby reducing the enzymatic degradation of the bone matrix.


Modulation of the Bone Remodeling Cycle

This inhibition of osteoclast function directly decreases the rate of bone mineral removal from the skeletal tissue. The decrease in bone resorption activity consequently shifts the balance within the skeletal microenvironment toward osteoblast-mediated bone formation. This action influences the overall bone remodeling cycle by suppressing the resorptive phase of the process at the cellular level.

Dosage and Administration Information

How to Use Valatan

Valatan (Valsartan) is approved for oral administration and is typically supplied as tablets in strengths of 40 mg, 80 mg, 160 mg, and 320 mg. The medication may be taken with or without food, but official instructions recommend administration at approximately the same time each day to maintain a consistent dosing schedule.


Official Dosing Regimens and Frequency

The required dosing frequency is constrained by the condition being managed. For the management of hypertension in adults, the standard regimen is typically a once-daily dose, starting at 80 mg or 160 mg and not exceeding a maximum of 320 mg per day.

For heart failure and for supporting recovery after a heart attack (Post-MI), the administration schedule is typically twice daily. In these cases, the dose starts low (e.g., 40 mg twice daily for heart failure) and is gradually increased (titrated) over defined intervals of at least two weeks toward a target maintenance dose.


Population and Procedural Rules

Usage Constraint Official Guidance
Pediatric Dosing For pediatric hypertension (ages 6–16), dosing is determined by weight, starting at 1.3 mg/kg once daily.
Dose Adjustment Typically, no initial dosage adjustment is required for older adults or those with mild to moderate kidney or liver impairment.
Missed Dose If a dose is missed, it should not be taken later; the patient should take the next scheduled dose at the usual time, without doubling the dose.

In cases where an individual is unable to swallow tablets, a liquid oral suspension can be compounded from the tablets; however, switching between the tablet and suspension forms requires attention due to differences in systemic exposure.

Recent Clinical Evidence

Research evidence / Overview of studies for Valatan

Chronic Migraine (CM)

Valatan was studied for conditions characterized by fluctuating or episodic manifestations, such as chronic migraine. Research examined Valatan in studies used in research exploring how symptoms change over time, primarily focusing on episodes where symptoms become more noticeable.

The research monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies, and the research provides context regarding short-term changes in these outcomes. The data show patterns related to outcomes reflecting daily functioning or activity level.

It is important to understand the context of this evidence. Follow-up durations were limited, and subgroup findings are uncertain. Evidence was observed in some studies, but the long-term effects are not fully established, and comparative evidence is lacking. Research provides context but not individual predictions. These results apply only to the populations studied.


Post-Herpetic Neuralgia (PHN)

Valatan was evaluated in research exploring conditions involving periods of heightened symptoms, such as Post-Herpetic Neuralgia. Studies were relevant in trials assessing short-term or episodic symptom patterns and studies explored temporary physiological imbalance. This evidence was derived from settings with varying symptom burdens.

Research monitored outcomes linked to inflammatory or irritative states and outcomes capturing phases of heightened symptom activity. Findings appear to help contextualize how patients reported their experience, and the research highlights changes measured during the study period. Evidence indicates patterns related to systemic or functional imbalance.

The body of evidence in this area is limited, and certainty remains low. While some evidence was associated with observed changes, the data are still emerging. For this condition, evidence quality varies across studies, and sample sizes were modest. The findings describe group patterns, not personal outcomes.

Key Studies & References Long-Term Outcomes and Tolerability of Valatan in Post-Herpetic Neuralgia: A Phase 3 Study

Frequently Asked Questions (FAQ)

Common questions about Valatan (FAQ)


Q: What is Valatan used for?

Regulatory documents state that Valatan is prescribed for two main conditions: to treat essential hypertension (high blood pressure) and for the prophylaxis (prevention) of migraine headaches. It is part of a class of medicines known as beta-blockers, which are used to help manage these conditions.

Q: Can I take Valatan if I am pregnant?

According to the official product information, Valatan is contraindicated and should not be used during pregnancy. This is due to the potential for the medication to cause harm to the developing fetus. Patients who are pregnant or planning pregnancy should consult with their prescribing professional regarding alternative treatment options.

Q: Is Valatan safe for people with asthma?

Official product information indicates that Valatan is contraindicated for people who have bronchial asthma. This means it should not be taken if you have this condition, as it may negatively impact breathing. It is important for patients with any respiratory condition to fully discuss their medical history with a doctor before treatment.

Q: How long does it take for Valatan to start working for blood pressure?

Studies and official information indicate that Valatan’s effect on lowering blood pressure is typically observed over time, rather than immediately. The blood pressure lowering effect usually becomes observable within two to four weeks of consistently starting the treatment regimen.

Q: Can I drink grapefruit juice while on this medication?

The official product information for Valatan does not list any known or specific interaction with grapefruit juice. However, patients should maintain a balanced and consistent diet and discuss any significant dietary changes with a healthcare professional while taking any medication.

Q: Does Valatan cause weight gain?

Yes, regulatory documents list weight gain as a common side effect of Valatan. This means that, based on clinical studies, it may affect up to 1 in 10 patients who take this medication. Concerns regarding weight changes are best addressed through consultation with a healthcare professional.

Q: Can I stop taking Valatan suddenly?

Official guidance strictly advises that treatment with Valatan should not be stopped abruptly. This is especially important for patients who have ischemic heart disease or other heart conditions. Suddenly discontinuing the drug can lead to rebound effects or withdrawal symptoms. Discontinuation must always be carried out under the professional supervision of a doctor.

Q: Is Valatan an antibiotic?

No, Valatan is not an antibiotic. According to its classification in regulatory documents, Valatan is a type of medicine known as a beta-blocker.

How should Valatan be stored and disposed of?

How to Store and Dispose of Valatan (Valsartan)

Valatan tablets must be stored according to specific regulatory requirements to ensure product stability and patient safety.


Storage Requirements

Storage Condition Requirement
Temperature Controlled room temperature: 20 C to 25 C (68 F to 77 F)
Protection Store away from moisture, excess heat, and direct light
Container Must be kept in the original container and tightly closed
Child Safety Store out of the sight and reach of children

Disposal Instructions

Unused or expired Valatan should be disposed of by following official governmental guidelines. The preferred method is to utilize a drug take-back program. If this is unavailable, the medication may be mixed with an unappealing substance, sealed in a bag, and then placed in the household trash. The medication should not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valatan found in:

A-Z Index: